About the Journal
Anticancer Intelligence publishes peer-reviewed, open-access research at the intersection of artificial intelligence and oncology, spanning computational methods, cancer genomics, imaging and pathology, therapeutic discovery including small molecules, biologics, nucleic acid therapeutics, optimized drug delivery systems, and clinical decision support. We also welcome rigorous anticancer research that incorporates emerging computational tools or provides empirical foundations for future machine learning applications.
ISSN: 3057-6636
Launched in 2026 as the flagship publication of the International Cancer Artificial Intelligence Research Institute (ICAIRI), Anticancer Intelligence was founded to give AI-driven oncology research a dedicated, rigorously reviewed home — at a time when this work is often scattered across broader computer science and clinical venues.
We welcome submissions from researchers at any career stage, anywhere in the world. Fee waivers are available for authors facing financial hardship. Browse our current issue, or read the Author Guidelines to get started.
